A valuable update on the multifaceted functions of the PTS

**PTS50 - The Prokaryotic Phosphoenolpyruvate: Sugar Phosphotransferase System**

50 Years After Its Discovery

Editor
Milton H. Saier

In 1964 Saul Roseman first described the phosphotransferase system (PTS) – a novel sugar-phosphorylating system in *Escherichia coli*. This compendium results from an international meeting held in Göttingen, Germany, during the summer of 2014 to commemorate the 50th anniversary of this discovery. A number of active researchers with a focus on the PTS reported their most recent findings concerning the structures, functions, mechanisms of action and physiological consequences of this complex system. The numerous aspects of the PTS, including a discussion regarding its impact on bacterial physiology, pathogenesis and ecology, are presented in this up-to-date compendium, which will provide a valuable source of information for many years to come.

Researchers, students and teachers of the physiology of archaebacteria and bacteria will find this compendium an essential source of reference. Additionally, biochemists and geneticists interested in the functions and mechanisms of complex enzyme systems, transport or regulatory systems in microbes will find this compendium a valuable source of information for many years to come.

The easiest way to order: www.karger.com

Karger – Medical and Scientific Publishers
CH-4009 Basel, Switzerland
orders@karger.com, f +41 61 306 12 34
www.karger.com
Chemotherapy

International Journal of Experimental and Clinical Chemotherapy

Founded 1959 as 'Chemotherapia' by H.P. Kuenmerle and P. Rentchnick

Editor-in-Chief
G. Minotti, Rome

Associate Editors
G. Delogu, Rome
G. Graziani, Rome

Editorial Board
A.M. Biroccio, Rome
C. Chiesa, Rome
S. Gemma, Siena
S. Horkovics-Kovats, Kundl
S. Kohno, Nagasaki
C. Landersdorfer, Parkville, Vic.
P. Linder, Geneva
K. Machka, Munich
P. Menna, Rome
E. Monti, Busto Arsizio
K.G. Naber, Straubing
R. Nau, Göttingen
P. Preziosi, Rome
E. Salvatorelli, Rome
M. Sanguinetti, Rome
G. Sava, Trieste
G.M. Shah, Quebec, Que.
F. Sörgel, Nuremberg-Heroldsberg
J.C. Stingl, Bonn
F. Van Bambeke, Brussels
M. Wilhelm, Nuremberg
Submission

Before submission, please read the Guidelines for Authors for specific requirements for manuscript preparation. Manuscripts written in English are considered and should be submitted online at www.karger.com/che (a link leads you to the Submission Website).

Submission of an article implies author agreement with the below Conditions. To be considered for publication, all manuscripts must be accompanied by a cover letter signed by all authors stating that the work has not been published, nor is it under consideration elsewhere, and that all authors approve the submission.

A Copyright Transfer Form, available on the Submission Website, with the corresponding author’s original (hand-written) signature must be received by the editorial office. Please print and sign the form, and upload it during submission (or fax or scan and email) to make it legally binding.

Names, postal and e-mail addresses of 4 international experts in the appropriate area of research should accompany each manuscript. At the Editors’ discretion scientist(s) selected from this list may be invited to act as referee(s). Referees suggested should not be from the same institution as the author.

Presentation of manuscripts should follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals [see International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication (April 2010 version). Available from: http://www.icmje.org].

In case of problems with submission, please contact:

che@karger.com

S. Karger AG – Medical and Scientific Publishers
Editorial Office ‘Chemotherapy’
Allschwilerstrasse 10
CH-4069 Basel (Switzerland)
Tel. +41 61 306 1361
Fax +41 61 306 1434

Conditions

All manuscripts are subject to editorial and peer review. Manuscripts are received with the explicit understanding that the work has not been published (wholly or in part), and is not under simultaneous consideration in any language elsewhere. Furthermore, all authors have made substantial contributions and confirm that they have seen and approved the manuscript submission. Submission of an article for publication implies the transfer of the copyright from the author to Karger Publishers upon acceptance. Accepted papers become the permanent property of the journal. If accepted, the Editor reserves the right to submit such letters to the authors of the articles concerned prior to publication in order to allow them to respond in the same issue of the journal. In exceptional cases, Letters to the Editor may also address data published in another journal or general subjects related to matters discussed in the journal. No abstract is required (maximum 1,200 words).

Arrangement

The preferred word processing program is MS-Word. The cover letter, the manuscript, the tables and the figures must be submitted in separate files. The manuscript file must contain all the text elements in the following order: title page, abstract and key words, main text, acknowledgments, references, table and figure legends. Tables and figures should be submitted as separate files according to the instructions below. Automatic line numbering should be used consecutively from the title page through to the final page. All pages should be numbered, starting from the title page, including tables, figure legends and figures.

Title page: The first page should contain the concise title of the article along with a short title for use as a running head, the full names of the authors and their affiliations (department, institute, hospital, university etc. where the work was conducted). The full postal address, telephone and fax numbers, as well as the e-mail address of the author to whom correspondence should be sent must be given at the bottom of the title page.

Key words: Please supply 3–10 key words that reflect the content of the paper.

Abstract: Each original paper needs an abstract of up to 250 words structured with subheadings as follows: Background/Aims, Methods, Results, Conclusions. Structured abstracts are not needed for Reviews and Novel Insights from Clinical Practice.

Footnotes: Footnotes should be avoided. When essential, they should be numbered consecutively and appear at the foot of the appropriate page.

Acknowledgements: Include all sources of funding for the research presented in the manuscript and substantive contributions of individuals regarding the research or manuscript. All possible conflicts of interest should also be given here.

Abbreviations: Abbreviations (with the exception of those clearly well-established in the field) should be explained when they are first used.

Units of measurement: Measurements should be expressed in SI units wherever possible.

Drug names: Use generic names of drugs (first letter: lowercase) whenever possible. Registered trade names (first letter: uppercase) should be marked with the superscript symbol ® or ™ when they are first mentioned.

Tables and illustrations: Tables and figures must be numbered (e.g., Figure 1, Figure 2) and submitted as separate files. Tables require a heading and a figure legend, which must provide sufficient information for either to stand alone. Each figure and table must be cited in the text numerically. Tables should be in Word format. b/w half-tone and color figures must have a final resolution of 300 dpi after scaling to final size, line drawings 1200 dpi. Color figures must be in RGB format. All figures should be in a common format such as PSD, TIF, PNG, EPS or WMF. Vector graphics should be in PPT, AI or EPS format.

Guidelines for Authors
Chemotherapy

Color Illustrations

Online edition: Color figures are reproduced free of charge.
In the print version, the figures are reproduced in black and white. The authors' names, colors in the text and figure legends should be avoided.

Print edition: Up to 6 color figures per page can be integrated within the text at CHF 960.00 per page.

References

Identify references in the text using Arabic numerals [in square brackets]. Do not alphabetize; number references sequentially in the order cited in the text. Material submitted for publication but not yet accepted should be referred to as [unpublished data] and should not be included in the reference list. A reference list should include only those publications which are cited in the text. Authors’ surnames should be followed by their initials with no punctuation other than a comma to separate individual authors. Preferably cite all authors (if not possible include at least 3 authors followed by et al). Abbreviate journal names according to the list of journals indexed for MEDLINE on the NLM website. Also see International Committee of Medical Journal Editors: Uniform Requirements for Manuscripts Submitted to Biomedical Journals (http://www.ICMJE.org).

Examples


Reference Management Software: The use of EndNote is recommended to facilitate formatting of citations and reference lists. The journal output style can be downloaded from http://endnote.com/downloads/styles.

Supplementary Material and Multimedia Files

Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Multimedia files enhance the online version of a publication. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, avi, mp3).

English Language Editing

For authors whose native language is not English, use of a professional language editing service prior to submission can help to avoid delays with the review process.

Digital Object Identifier (DOI)

A DOI number will be available as a unique identifier on the title page of each article. DOIs are useful for identifying and citing articles published online without volume or issue information (for more information, see www.doi.org).

Self-Archiving/Green Open Access

Karger permits authors to archive their pre-prints (i.e. peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution’s internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:
- Be used for noncommercial purposes only
- Be linked to the final version on www.karger.com
- Include the following statement:

‘This is the peer-reviewed but unlabeled manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/doi-9-[insert DOI number]’.

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author’s behalf (see Funding Organizations (NIH etc.)).

For self-archiving Author’s ChoiceM service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com.

Author’s ChoiceM

Karger’s Author’s ChoiceM service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com.

The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation.

More information can be found at www.karger.com/authors_choice.

The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license.

Reprints

An order form with a price list can be requested when returning the corrected proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

Funding Organizations (NIH etc.)

The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author’s ChoiceM, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC. Authors should include information on their grants in the Acknowledgements section of their papers.

Copy Editing

Manuscripts accepted for publication by Karger Publishers are subject to copy editing.

Proofs

An email containing a link to download the proofs will be sent to the corresponding author. Proofs should be returned within 48 hours. Alterations made in proofs, other than the correction of printer’s (introduced) errors, are charged to the author and may require editorial approval.

Page Charges

There is no page charge for papers of 3 or fewer printed pages (including tables, illustrations and references). Authors are charged CHF 325.00 for each additional complete or partial printed page.

KARGER
E-Mail karger@karger.com
www.karger.com
© 2016 S. Karger AG, Basel
The Journal Home Page is available at: www.karger.com/che
Contents

See the journal website for contents
Turning a new page in virology

Mimivirus, Marseillevirus and Megavirales: The Emerging Field of Giant Viruses

Editors
D. Raoult
G. Greub

At the beginning of the 21st century, a microorganism which was visible under the microscope, could be Gram-stained and had been considered a bacterium for several years was identified as Mimivirus, the largest virus known at the time. This opened up the world of giant viruses which are today considered to represent a fourth domain of microbes.

In this special issue of Intervirology, recent findings on two new families of giant viruses, Marseilleviridae and Mimiviridae, are presented. The data confirm that both groups of viruses may be found in the environment (soil, water, insects) and in humans (blood, stool). New techniques to culture, purify and isolate these viruses are also reported. These new findings show that the world of giant viruses is expanding, and challenge the traditional classification of microbes into three domains (bacteria, archaea and eukaryotes) based on size and ribosomal genes. A new classification of microbes into four branches – giant viruses (Megavirales), bacteria, archaea and eukaryotes – is postulated which reflects more realistically our current knowledge of the microbial world.

Anyone interested in this revolution in virology should read this publication which may contribute to the discovery of further giant viruses that are as yet unknown.

Contents

• Editorial: A Need to Discover the World of Giant Viruses: Raoult, D.

• TRUC or the Need for a New Microbial Classification: Raoult, D.

• A Decade of Improvements in Mimiviridae and Marseilleviridae Isolation from Amoeba: Pagnier, I.; Reteno, D.-G.I.; Saadi, H.; Boughalmi, M.; Gaia, M.; Slimani, M.; Ngounga, T.; Bekliz, M.; Colson, P.; Raoult, D.; La Scola, B.

• Codon Usage, Amino Acid Usage, Transfer RNA and Amino-Acyl-tRNA Synthetases in Mimiviruses: Colson, P.; Fournous, G.; Diene, S.M.; Raoult, D.

• Giant Viruses of Amoebae as Potential Human Pathogens: Colson, P.; La Scola, B.; Raoult, D.

• First Isolation of a Marseillevirus in the Diptera Syrphidae Eristalis tenax: Boughalmi, M.; Pagnier, I.; Aherfi, S.; Colson, P.; Raoult, D.; La Scola, B.

• Describing the Silent Human Virome with an Emphasis on Giant Viruses: Popgeorgiev, N.; Temmam, S.; Raoult, D.; Desnues, C.

• Real-Time PCR Systems Targeting Giant Viruses of Amoebae and Their Virophages: Ngounga, T.; Pagnier, I.; Reteno, D.-G.I.; Raoult, D.; La Scola, B.; Colson, P.

• Shan Virus: A New Mimivirus Isolated from the Stool of a Tunisian Patient with Pneumonia: Saadi, H.; Reteno, D.-G.I.; Colson, P.; Aherfi, S.; Minodier, P.; Pagnier, I.; Raoult, D.; La Scola, B.

• Lausannevirus Seroprevalence among Asymptomatic Young Adults: Mueller, L.; Baud, D.; Bertellli, C.; Greub, G.

• Alcohol Disinfection Procedure for Isolating Giant Viruses from Contaminated Samples: Slimani, M.; Pagnier, I.; Boughalmi, M.; Raoult, D.; La Scola, B.

Author Index/Subject Index
An in-depth compendium of current knowledge of chromosome dynamics and arrangement in bacteria and archaea

Bacterial Chromosomal Segregation

Editor
Peter L. Graumann

All cellular life depends on the accurate duplication and partitioning of the genome. It has become clear in recent years that the chromosomes of many bacterial species show a well-defined arrangement, and their layout, integrity and segregation is supported by a variety of conserved proteins. The architecture of the chromosome also has a large impact on global transcription, and proteins involved in the topology of the DNA play major roles in chromosome segregation and compaction. In this special issue, the molecular biological principles of these fundamental processes are described in several model and non-model bacteria.

Providing an in-depth compendium of our current knowledge of chromosome dynamics and arrangement in bacteria and archaea, this publication is a must-read for any researcher studying or teaching bacterial genetics or physiology.

Contents

Introduction

Chromosome Architecture and Segregation in Prokaryotic Cells:
Graumann, P.L.

Review Articles

Dynamic Organization: Chromosome Domains in Escherichia coli:
Messerschmidt, S.J.; Waldminghaus, T.

Function of Nucleoid-Associated Proteins in Chromosome Structuring and Transcriptional Regulation:
Dorman, C.J.

Order from the Order: How a Spatiotemporal Genetic Program Is Encoded in a 2-D Genetic Map of the Bacterial Chromosome:
Muskhelishvili, G.; Travers, A.

Genomic Looping: A Key Principle of Chromatin Organization:
van der Valk, R.A.; Vreede, J.; Crémazy, F.; Dame, R.T.

Chromosome Segregation in Vibrio cholera:
Ramachandran, R.; Jha, J.; Chattonaj, D.K.

MukBEF, a Chromosomal Organizer: Rybenkov, V.V.; Herrera, V.; Petrushenko, Z.M.; Zhao, H.

Structural Maintenance of Chromosome Complex in Bacteria:
Kleine Borgmann, L.A.K.; Graumann, P.L.

The FtsK Family of DNA Translocases Finds the Ends of Circles:
Crozat, E.; Rousseau, P.; Fournes, F.; Cornet, F.

Polyploidy in Archaea and Bacteria: About Desiccation Resistance, Giant Cell Size, Long-Term Survival, Enforcement by a Eukaryotic Host and Additional Aspects:
Soppa, J.

Archaeal Chromosome Biology:
Samson, R.Y.; Bell, S.D.

Author Index/Subject Index
Introducing the new interdisciplinary Karger journal

Biomedicine Hub is an interdisciplinary journal: a ‘hub’ for researchers, clinicians and public health professionals across biomedical disciplines to share research findings, ideas, theories, experimental results and clinical experience. Biomedicine Hub aims at facilitating the exchange of knowledge between disciplines, with a focus on translational science for the development of cutting-edge technologies and the improvement of health care. A further focus is on emerging interdisciplinary fields at the forefront of medicine.

Karger premium quality – open access – peer-reviewed – rapid publication

Get the full picture on www.biomedicinehub.com

- 16 internationally renowned senior editors
- over 170 Editorial Board Members
- from 35 countries
- specialized in 41 medical disciplines

We invite you to submit now!
Article Processing Charges (APC) are waived before June 30, 2016.
www.karger.com/bmh_guidelines

Visit us on Facebook
### Antimicrobial Section

#### Original Papers

72 **Multidrug-Resistant *Escherichia coli* Strains Isolated from Patients Are Associated with Class 1 and 2 Integrons**  
Lavakhamseh, H. (Sanandaj); Mohajeri, P. (Kermanshah); Rouhi, S.; Shakib, P.; Ramazanzadeh, R.; Rasani, A.; Mansouri, M. (Sanandaj)

87 **First Detection of OXA-10 Extended-Spectrum Beta-Lactamases and the Occurrence of *mexR* and *nfxB* in Clinical Isolates of *Pseudomonas aeruginosa* from Nigeria**  
Odumosu, B.T. (Lagos/Ibadan/Lucknow); Adeniyi, B.A. (Ibadan); Chandra, R. (Lucknow)

### Anticancer Section

#### Original Papers

57 **The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study**  

65 **Chemotherapy Regimen in Nonagenarian Cancer Patients: A Bi-Institutional Experience**  
Rivoirard, R. (Clermont-Ferrand); Chargari, C. (Paris); Kullab, S.; Trone, J.-C.; Langrand-Escure, J. (Saint-Priest-en-Jarez); Moriceau, G. (Clermont-Ferrand); Guy, J.-B. (Saint-Priest-en-Jarez); Annede, P.; Méry, B. (Clermont-Ferrand); Moncharmont, C. (Saint-Priest-en-Jarez); Falk, A.T. (Nice); Vedrine, L. (Paris); Merrouche, Y.; Fournel, P.; Magné, N. (Saint-Priest-en-Jarez)

77 **Prognostic Impact of the ABCC11/MRP8 Polymorphism in Adjuvant Oral Chemotherapy with S-1 for Non-Small Cell Lung Cancer**  
Tsuchiya, T.; Arai, J.; Matsumoto, K.; Miyazaki, T.; Honda, S. (Nagasaki); Tagawa, T. (Omura); Nakamura, A. (Sasebo); Taniguchi, H.; Sano, I. (Nagasaki); Akamine, S. (Oita); Muraoka, M. (Isahaya); Hisano, H.; Yamazaki, N.; Nagayasu, T. (Nagasaki)

93 **A Phase II Study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer**  
Kasai, T. (Utsunomiya); Nakamura, Y.; Fukuda, M.; Kitazaki, T.; Nagashima, S.; Takatani, H. (Nagasaki); Nakano, H. (Saga); Nakatomi, K.; Ikeda, T.; Yamaguchi, H. (Nagasaki); Tsukamoto, K. (Sasebo City); Oka, M. (Okayama); Kohno, S. (Nagasaki)

99 **Comparison of Safety and Efficacy of Different Models of Target Vessel Regional Chemotherapy for Gastric Cancer with Liver Metastases**  
Chen, H.; Gao, S.; Yang, X.-Z. (Beijing); Chen, L.-J. (Tianjin); Liu, P.; Xu, H.-F. (Beijing)

#### Novel Insights from Clinical Practice

108 **Two Fatal Cases of Accidental Intrathecal Vincristine Administration: Learning from Death Events**  
Chotsampancharoen, T.; Sripornsawan, P.; Wongchanchailert, M. (Hat-Yai)